{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:57Z","timestamp":1791910857555,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.tcm.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:52:35Z","timestamp":1747396355000},"page":"468-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The role of finerenone in heart failure"],"prefix":"10.1016","volume":"35","author":[{"given":"Hassan","family":"Ismahel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tcm.2025.05.002_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"13","key":"10.1016\/j.tcm.2025.05.002_bib0002","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases-clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.tcm.2025.05.002_bib0003","doi-asserted-by":"crossref","unstructured":"Pitt B., Zannad F., Remme Willem J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med.341(10):709\u201317.","DOI":"10.1056\/NEJM199909023411001"},{"key":"10.1016\/j.tcm.2025.05.002_bib0004","doi-asserted-by":"crossref","unstructured":"Zannad F., McMurray John J.V., Krum H., van Veldhuisen Dirk J., Swedberg K., Shi H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl J Med.364(1):11\u201321.","DOI":"10.1056\/NEJMoa1009492"},{"issue":"18","key":"10.1016\/j.tcm.2025.05.002_bib0005","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.tcm.2025.05.002_bib0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.tcm.2025.05.002_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"46","key":"10.1016\/j.tcm.2025.05.002_bib0008","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","article-title":"Adverse effects of mineralocorticoid receptor antagonist administration","volume":"24","author":"Kallistratos","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.tcm.2025.05.002_bib0009","doi-asserted-by":"crossref","unstructured":"Pitt B., Pfeffer Marc A., Assmann Susan F., Boineau R., Anand Inder S., Claggett B., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med.370(15):1383\u201392.","DOI":"10.1056\/NEJMoa1313731"},{"issue":"16","key":"10.1016\/j.tcm.2025.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker Stefan","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2025.05.002_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"issue":"6","key":"10.1016\/j.tcm.2025.05.002_bib0012","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.tcm.2025.05.002_bib0013","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41371-020-0360-2","article-title":"Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective","volume":"35","author":"Fuller","year":"2021","journal-title":"J Hum Hypertens"},{"issue":"6","key":"10.1016\/j.tcm.2025.05.002_bib0014","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"4 Pt 1","key":"10.1016\/j.tcm.2025.05.002_bib0015","first-page":"E657","article-title":"Determinants of cardiac fibrosis in experimental hypermineralocorticoid states","volume":"269","author":"Young","year":"1995","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.tcm.2025.05.002_bib0016","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J Mol Cell Cardiol"},{"issue":"18","key":"10.1016\/j.tcm.2025.05.002_bib0017","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.110.954388","article-title":"Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum","volume":"123","author":"Borlaug","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.tcm.2025.05.002_bib0018","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2025.05.002_bib0019","doi-asserted-by":"crossref","unstructured":"Weber Karl T. Aldosterone in congestive heart failure. N Engl J Med.345(23):1689\u201397.","DOI":"10.1056\/NEJMra000050"},{"key":"10.1016\/j.tcm.2025.05.002_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2025.05.002_bib0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-3565(25)25602-6","article-title":"Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone","volume":"126","author":"Kagawa","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"issue":"3281","key":"10.1016\/j.tcm.2025.05.002_bib0022","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","article-title":"Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt","volume":"126","author":"Kagawa","year":"1957","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.tcm.2025.05.002_bib0023","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ndt\/gfab328","article-title":"Spironolactone and chlorthalidone-old drugs, new uses-but approach with caution","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transpl"},{"issue":"7","key":"10.1016\/j.tcm.2025.05.002_bib0024","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.tcm.2025.05.002_bib0025","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.tcm.2025.05.002_bib0026","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/cpt1977215602","article-title":"Spironolactone and canrenoate-K: relative potency at steady state","volume":"21","author":"Ramsay","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"8481","key":"10.1016\/j.tcm.2025.05.002_bib0027","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(86)92856-4","article-title":"Gynaecomastia after spironolactone and potassium canrenoate","volume":"1","author":"Bellati","year":"1986","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tcm.2025.05.002_bib0028","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"issue":"39","key":"10.1016\/j.tcm.2025.05.002_bib0029","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.tcm.2025.05.002_bib0030","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.tcm.2025.05.002_bib0031","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"10.1016\/j.tcm.2025.05.002_bib0032","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, In Vivo and In vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.tcm.2025.05.002_bib0033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.tcm.2025.05.002_bib0034","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone reduces intrinsic arterial stiffness in Munich wistar fr\u00f6mter rats, a genetic model of chronic kidney disease","volume":"51","author":"Gil-Ortega","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.tcm.2025.05.002_bib0035","doi-asserted-by":"crossref","unstructured":"Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348(14):1309\u201321.","DOI":"10.1056\/NEJMoa030207"},{"issue":"1","key":"10.1016\/j.tcm.2025.05.002_bib0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.tcm.2025.05.002_bib0037","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2025.05.002_bib0038","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.tcm.2025.05.002_bib0039","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.tcm.2025.05.002_bib0040","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris George","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.tcm.2025.05.002_bib0041","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tcm.2025.05.002_bib0042","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"31","key":"10.1016\/j.tcm.2025.05.002_bib0043","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.tcm.2025.05.002_bib0044","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.tcm.2025.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon Scott","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2025.05.002_bib0046","unstructured":"Docherty K.F., Henderson A.D., Jhund P.S., Claggett B.L., Desai A.S., Mueller K., et al. Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation.0(0)."},{"issue":"8","key":"10.1016\/j.tcm.2025.05.002_bib0047","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.tcm.2025.05.002_bib0048","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.tcm.2025.05.002_bib0049","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.tcm.2025.05.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","article-title":"Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF","volume":"17","author":"Chimura","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.tcm.2025.05.002_bib0051","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2024.4613","article-title":"Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2025.05.002_bib0052","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2025.05.002_bib0053","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2025.05.002_bib0054","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2025.05.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:30:21Z","timestamp":1756211421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173825000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1050173825000659"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2025.05.002","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of finerenone in heart failure","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}